ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0457

Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening

Pratyusha Banik1, Melody Andrews1, Sudhakar Pipavath1 and Namrata Singh2, 1University of Washington, Seattle, WA, 2University of Washington, Bellevue, WA

Meeting: ACR Convergence 2025

Keywords: Oncology, pulmonary, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of lung cancer with shared risk factors being heavy smoking history and possibly interstitial lung disease (ILD). They highlight the importance of lung cancer screening in persons with RA that meet age and smoking history criteria. However there have not been many studies examining the radiographic findings among persons with RA that undergo chest computed tomography (CT) for lung cancer screening. The objectives of our study were to evaluate the yield of lung cancer diagnoses in those with RA that underwent lung cancer screening with low dose CT chest, and to characterize the pattern of lung nodules and pulmonary parenchymal findings in this cohort.

Methods: We identified all adults ( >18 years of age) with an ICD10 diagnostic code of RA between March 2021 and October 2023, that follow with rheumatology providers at our academic center. We then used the procedure code for lung cancer screening with chest CT (72171) to identify patients with RA that met the United States Preventative Task Force (USPSTF) criteria for lung cancer screening CT, and who had undergone at least one CT scan. We conducted chart review to extract patient characteristics and lung imaging data such as age, sex duration of RA, rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) status, smoking pack year history, nodule characteristics, presence of ILD, and lung cancer diagnosis.

Results: 42 patients met the inclusion criteria. The majority were female (62%). 66% were RF positive and 64% were CCP positive. Of the 42 patients with RA who underwent lung cancer screening, one ( 2.4%) was diagnosed with lung cancer (squamous cell carcinoma) on follow up imaging. The majority (80%) had benign lung nodules with Lung-RADS(Lung Imaging Reporting and Data System) category 1 or 2, and 9.5% had suspicious findings (Lung-RADS 4A). Nodules > 6 mm were found in 17% and calcified nodules suggestive of prior granulomatous disease were seen in five patients. Nodule density varied with solid, pure ground glass, part solid, and mixed patterns observed. Interstitial lung abnormalities or interstitial lung disease was seen in 17%, and showed no association with Lung-RADS category.

Conclusion: Among patients with RA who met criteria for lung cancer screening, the diagnostic yield for malignancy was low, and most lung nodules were benign. Nonetheless, a notable proportion had suspicious findings requiring follow-up. These results highlight the importance of targeted lung cancer screening in RA, particularly for individuals with significant smoking history, and support ongoing vigilance in radiographic surveillance for early detection and management.

Supporting image 1Table 1: Patient characteristics

Supporting image 2Figure 1A: Lung-RADS Category Assessment of Nodules

Supporting image 3Figure 1B: Nodule Density


Disclosures: P. Banik: None; M. Andrews: None; S. Pipavath: None; N. Singh: None.

To cite this abstract in AMA style:

Banik P, Andrews M, Pipavath S, Singh N. Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pulmonary-profiles-characterizing-lung-findings-in-rheumatoid-arthritis-patients-undergoing-lung-cancer-screening/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-profiles-characterizing-lung-findings-in-rheumatoid-arthritis-patients-undergoing-lung-cancer-screening/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology